Ipratropium treatment for rhinorrhoea in patients with perennial rhinitis. An open follow-up study of efficacy and safety

Publisher Website
Google Scholar
Abstract
The efficacy and safety of intranasal ipratropium therapy for rhinorrhea were tested in an open follow-up study of 20 adult patients with perennial rhinitis. The reduction of nasal hypersecretion of 40-45% obtained with 80 .mu.g 4 times daily in a placebo-controlled study was maintained over the next 4 wk although the mean daily dose was reduced to 180 .mu.g. The spray treatment was well tolerated and rhinoscopy, measurements of the sense of smell and the secretory responsiveness of the nose before and 10-48 mo. after the start of the trial did not reveal any signs of serious local adverse effects. Ipratropium nasal spray is evidently effective in the treatment of rhinorrhea and appears to be safe for long-term use.